Clinical Trial: Hyperprogression in PD-L1 >= 50% NSCLC: a Biomarker Guided Phase 2 Trial

U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274384) titled 'Hyperprogression in PD-L1 >= 50% NSCLC: a Biomarker Guided Phase 2 Trial' on Sept. 17.

Brief Summary: In metastatic NSCLC patients with PD-L1 expression >=50%, a circulating immature (CD10-) LDNs level of >=30.5% confers a high risk of hyperprogression (HPD) with first line single-agent immune-checkpoint inhibitors (SA-ICI). HPD is defined as a tumor growth rate (TGR) delta >=50% between pre-treatment and post-treatment, and/or a TGR ratio >=2. The combination of platinum-based chemotherapy (PCT) with ICI in this setting could prevent the occurrence of HPD and ultimately improve survival outcomes.

This randomized, multicentric, ope...